Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck

Medical Oncology

Volumn 23, Issue 4, 2006, Pages 463-470

  Kandiloros, D ^a   Eleftheriadou, Anna ^a,c   Chalastras, T ^a   Kyriou, L ^b   Yiotakis, I ^a   Ferekidis, E ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

CEA; CYFRA 21 1; Diagnosis; SCCA; Squamous cell carcinoma of head and neck; TPA M; Tumor markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOKERATIN 19 FRAGMENT; SQUAMOUS CELL CARCINOMA ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG SPECIFICITY; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION;

AGED; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KERATINS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SERPINS; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 33846999927     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:4:463     Document Type: Article

References (32)

1. Forastiere A, Koch W, Trotti A, Sidransky D. Medical progress-head and neck cancer. N Engl J Med 2001; 345: 1890-1900.
2. Landis SH, Murray T, Bolden S, Wingo PO. Cancer statistics. CA Cancer J Clin 1998; 48: 6-29.
3. Spitz MR. Epidemiology and risk factors for head and neck cancer. Semin Oncol 1994; 21: 281-288.
4. Fujieda S. Prognostic factors for head and neck cancer. Gan To Kagaku Ryoho 2001; 28 (Review Japanese)(4): 440-447.
5. Dietz A. Epidemiology of laryngeal cancer. Laryngorhinootologie 2004; 83(11): 771-772.
6. Schroder M, Meyer T. CEA studies in squamous cell carcinoma of the head and neck. HNO 1986; 34: 334-342.
7. Straka M, Wagner R, Johnson J, Kachman K, Eibling D. The lack of utility of a tumour marker panel in head and neck carcinoma. Arch Otolaryng Head Neck Surg 1992; 118: 802-805.
8. Rassekh C, Johnson J, Eibling E. Circulating markers in squamous cell carcinoma of the head and neck: a review. Oral Oncol Eur J Cancer 1994; 30B: 23-28.
9. Copper MP, Braakhuis JM, De Vries N, Van Dongen GA, Nauta J, Snow GB. A panel of biomarkers of carcinogenesis of the upper aerodigestive tract as potential intermediate endpoints in chemoprevention trials. Cancer Lett 1993; 71(3): 825-830.
10. Carbayo M, et al. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem 1999; 45: 1944-1953.
11. Deng YF, et al. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J of Laryngol & Otol 2003; 117: 190-194.
12. Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004; 37(7): 529-540.
13. Ho S, Leung WT, Yuen J, Jonhson PJ. Serum levels of CYFRA 21-1 in nasopharyngeal carcinoma and its possible role in monitoring of therapy. Oral Oncol Eur. J. Cancer 1996; 32B(6): 377-380.
14. Molina R, et al. Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC. Anticancer Res 1995; 15: 479-484.
15. Tannapfel A, Weber A. Tumor markers in squamous cell carcinoma of the head and neck: clinical effectiveness and prognostic value. Eur Arch Otorhinolayngol 2001; 258: 83-88.
16. Ogawa T, et al. Comparison of tumor markers in patients with suamous cell carcinoma of the head and neck. Acta Otolaryngol (Stockh) 1999; 540(Suppl): 72-76.
17. Rosati G, Riccardi F, Tucci A. Use of tumor markers in the management of head and neck cancer. Int J Biol Markers 2000; 15(2): 179-183.
18. Becciolini A, Porciani S, Lanini A, Tommasi M, Olmi P, Chiavacci A. Prognostic significance of tissue polypeptide antigen (TPA) in head and neck carcinomas. Acta Otolaryngol 1993; 32(3): 295-299.
19. Doweck I, Barak M, Greenberg E, Uri N, Kellner J, Lurie M. Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryng Head Neck Surg 1995; 121: 177-181.
20. Banal A, Hacene K, Berthelot-Ruff E, Mahe E, Fontana X, Pichon MF. Comparison of Cyfra 21-1 and SCCassays in head and neck tumours. Tumour Biol. 2001; 22(1): 27-35.
21. Niemann AM, Goeroegh T, Gottschlich S, Lippert BM, Werner JA. Cut off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN). Anticancer Res 1997; 17: 2859-2860.
22. Ma B, et al. Prospective validation of serum CYFRA 21-1, β-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy. Cancer Lett 2004; 101(4): 776-781.
23. Nagler RM, Barak M, Peled M, Ben-Aryeh H, Filatof M, Laufer D. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer/Radiotherapy 1999; 85(5): 1018-1025.
24. Tai CJ, Liu FY, Liang JA, Yang SN, Tsai MH, Kao CH. Comparison of Cyfra 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma. Anticancer Res 2002; 22: 3793-3796.
25. Nap M, Van Wek T, Andres C, Bellanger L. Immunohistochemical profiles of 30 monoclonal antibodies against cytokeratin 8, 18 and 19. Tumor Biol 2001; 22: 4-10.
26. Hamakawa H, Bao Y, Takarada M, Fukuzumi M, Tanioka H. Cytokeratin expression in squamous cell carcinoma of the lung and oral cavity. An immunohistochemical study with possible clinical relevance. Oral Surgery Oral Medicine Oral Pathology 1998; 85(4): 438-443.
27. Kulpa J, Stasik Z, Skolyszewski J, Wojcik E, Rychlik U, Pudelek K. Predictive value of SCC-Ag, CYFRA 21-1 and selected acute phase proteins in radiotherapy of pharyngeal and laryngeal cancer. A preliminary report. Neoplasma 2004; 51(2): 103-109.
28. Bongers V, Braakhuis JM, Snow GB. Circulating fragments of cytokeratin 19 in patients with head and neck squamous cell carcinoma. Clin Otolaryngol 1995; 20: 479-482.
29. Kuropkat C, Lippert BM, Werner JA. Follow-up with serum cyfra 21-1 in patients with squamous sell carcinoma of the head and neck. Oncology 2002; 63: 280-285.
30. Lin WY, Yen TC, Cheng KY, Wang SJ. The value of Cyfra 21-1, a new tumor marker, in nasopharyngeal carcinoma. Neoplasma 1998; 45(1): 21-24.
31. Lee JK, Hsieh JF, Tsai SC, Ho YJ, Sun SS, Kao CH. Comparison of Cyfra 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol. 2001; 110(8): 775-778.
32. Yen TC, Lin WY, Kao CH, Cheng KY, Wang SJ. A study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol 1998; 23: 82-86.